Patient Engagement Software Market Size, Trends, and Growth Forecast (2025-2032)
The patient engagement software industry is witnessing rapid evolution as healthcare providers increasingly adopt digital solutions to enhance patient experience and streamline communication.
This surge in adoption aligns with rising demands for efficient care coordination and improved health outcomes, driving significant business growth across global markets.
Market Size and Overview
The patient engagement software market is estimated to be valued at USD 9.73 Billion in 2025 and is expected to reach USD 34.46 Billion by 2032, growing at a compound annual growth rate (CAGR) of 19.8% from 2025 to 2032.
This strong Patient Engagement Software Market growth is propelled by rising healthcare digitalization and regulatory emphasis on patient-centric care models. The evolving industry trends emphasize integration with electronic health records (EHR) and advanced analytics to optimize patient interaction and satisfaction levels.
Market Segments
The Patient Engagement Software market is segmented primarily into deployment modes, end-users, and functionalities.
- Deployment Modes: Cloud-based and on-premises, where cloud-based solutions dominate due to scalability and lower upfront costs, with adoption increasing by over 30% in healthcare facilities in 2024.
- End Users: Hospitals, ambulatory care centers, and specialty clinics. Hospitals hold a dominant position owing to their larger patient base and complex care pathways, while ambulatory care centers show the fastest growth, leveraging mobile engagement tools.
- Functionalities: Appointment scheduling, patient communication, remote monitoring, and patient education. Among these, patient communication platforms witnessed a 25% revenue increase in 2024, driven by telehealth expansion and value-based care initiatives.
‣ Get more insights on: Patient Engagement Software Market
‣ Get this Report in Japanese Language: 患者エンゲージメントソフトウェア市場
‣ Get this Report in Korean Language: 환자참여소프트웨어시장
coherentMI@13